Breast Cancer Vaccine Tests German Merck KGaA’s $1 Billion Strategy

Bookmark and Share

Bloomberg -- Merck KGaA of Germany is gambling an unproven therapy that spurs the immune system to attack cancer cells will increase its share of a $48 billion oncology market.

MORE ON THIS TOPIC